ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
NexImmune Inc

NexImmune Inc (NEXI)

3.93
0.00
( 0.00% )
Updated: 20:00:00

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
3.93
Bid
3.46
Ask
3.51
Volume
-
0.00 Day's Range 0.00
1.2501 52 Week Range 28.405
Market Cap
Previous Close
3.93
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
744,158
Shares Outstanding
1,371,051
Dividend Yield
-
PE Ratio
-0.17
Earnings Per Share (EPS)
-23.59
Revenue
-
Net Profit
-32.34M

About NexImmune Inc

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseas... NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
NexImmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NEXI. The last closing price for NexImmune was $3.93. Over the last year, NexImmune shares have traded in a share price range of $ 1.2501 to $ 28.405.

NexImmune currently has 1,371,051 shares outstanding. The market capitalization of NexImmune is $5.39 million. NexImmune has a price to earnings ratio (PE ratio) of -0.17.

NEXI Latest News

Approbation des résultats financiers du groupe au 31 mars 2024, poursuite de la croissance et de l’augmentation de la marge de BAIIA, lancement d’un programme de rachat d’actions de 500 millions €

Chiffre d’affaires de 781,6 millions € au 1er trimestre 2024, +6,0 % en glissement annuel BAIIA à 361,7 millions € au 1er trimestre 2024, +8,6 % en glissement annuel, avec une augmentation de...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
41.1340.35714285712.87.04992.0138378033.92367596CS
120.825.55910543133.137.04992.017441583.91554006CS
26-1.26-24.27745664745.1928.4052.016458588.49621423CS
52-3.4125-46.47599591427.342528.4051.25018203237.6304439CS
156-262.82-98.526710403266.75469.51.250160614724.60833708CS
260-571.32-99.3168187744575.256951.250153643734.43063478CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
POAIPredictive Oncology Inc
$ 1.955
(82.71%)
137.18M
PBMPsyence Biomedical Ltd
$ 0.655
(67.35%)
65.44M
SLRXSalarius Pharmaceuticals Inc
$ 3.51
(64.02%)
17.2M
XCURExicure Inc
$ 0.5225
(30.99%)
21.24M
GSHDGoosehead Insurance Inc
$ 86.04
(30.96%)
589.05k
TWOU2U Inc
$ 1.66
(-59.71%)
3.27M
CTNTCheetah Net Supply Chain Service Inc
$ 0.2861
(-40.64%)
4.05M
KDLYKindly MD Inc
$ 1.95
(-39.44%)
552.48k
EZFLEzFill Holdings Inc
$ 3.789
(-39.13%)
103.92k
SLGLSol Gel Technologies Ltd
$ 0.44
(-34.33%)
12.85M
NVDANVIDIA Corporation
$ 115.07
(0.72%)
239.51M
POAIPredictive Oncology Inc
$ 1.955
(82.71%)
137.18M
SLNASelina Hospitality PLC
$ 0.0399
(-12.69%)
135.22M
SQQQProShares UltraPro Short QQQ
$ 9.01
(-0.55%)
127.32M
PBMPsyence Biomedical Ltd
$ 0.655
(67.35%)
65.44M

NEXI Discussion

View Posts
TrendTrade2016 TrendTrade2016 2 weeks ago
lol...only on the internet do peeps talk such nonsense...how about a dolla next...they worked the clowns nicely
👍️0
StockItOut StockItOut 2 weeks ago
The 200 day low came up on everyone's scanner, so of course you can see it when you scan only after the breakout. LOL.
👍️0
Zardiw Zardiw 2 weeks ago
$NEXI +157% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z
👍️0
Renee Renee 2 weeks ago
NEXI delisted from the Nasdaq to the OTC, yet the stock ran from $2.30 to $7.04, over 300%. High volume of +34 million. Stock dropped back down to $3-ish. Those who bought at $7.04 are down about 45%.....ouch.

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
TrendTrade2016 TrendTrade2016 2 weeks ago
LOOK OUT...LOOK OUT...SHES TAKING IN WATER!!!
👍️0
TrendTrade2016 TrendTrade2016 2 weeks ago
OUCH....NexImmune reported earnings per share of -$4.99....The company did not report any revenue for the quarter.
👍️0
Invest-in-America Invest-in-America 2 weeks ago
NEXI: Maybe, after it hits $15.00!!!
👍️0
TrendTrade2016 TrendTrade2016 2 weeks ago
NEXI GONNA DROP HARD....ALGOS SETTING UP EVERYTHING FOR SHORTS
👍️0
Invest-in-America Invest-in-America 2 weeks ago
NEXI: To dah MOON!!!! (Who would-ah thunk it????)
👍️0
tw0122 tw0122 2 weeks ago
Boom time $3.90
👍️0
Monksdream Monksdream 3 months ago
NEXI under $5
👍️0
lmcl123 lmcl123 6 months ago
Disclosure; I have not purchased this stock and would not touch it with a ten foot pole!
I've been watching the shenanigans with this company for the last few months and wondered why the stock of a company that was going out of business would be sought after so heavily and be so volatile . I came to the conclusions of 1) some kind of short squeeze, or 2) a knight in shining armor was coming in at the eleventh hour to save the company, and some people (I think the term for this is "insider") in the know were doing some market manipulation to make a little more bank$. The following press release is, at least, part of the answer!

GAITHERSBURG, Md. , Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 304,731 shares of its common stock. The unregistered warrants to be issued in this private placement will have an exercise price $12.05 per share, will become exercisable immediately upon issuance and have a term of two years from the date of issuance. The closing of the offering is expected to occur on or about February 6, 2024 , subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $3.67 million , before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering to seek additional financing and pursue potential business development and/or collaboration opportunities, and for working capital and general corporate purposes.
As previously disclosed in January 2024 , the Company adjourned its special meeting of stockholders for the purpose of approving the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the “Special Meeting”), with the Special Meeting scheduled to reconvene on Wednesday, February 7, 2024 , at 10:00 a.m., Eastern Time in a virtual format. As a result of this offering, the Company expects to postpone the Special Meeting.
The shares of common stock (or common stock equivalents) offered in the registered direct offering (but excluding the unregistered warrants and the shares of common stock underlying such unregistered warrants) described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-263399), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on March 9, 2022 , and declared effective by the SEC on March 16, 2022 . The offering of the shares of common stock (or common stock equivalents) to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue , 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
The offer and sale of the unregistered warrants are being made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506(b) of Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered warrants and the underlying shares of common stock may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. 
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
👍️0
wickerman wickerman 6 months ago
$NEXI yep the old rug pull this market is rigged to the core first it destroys shorts then longs.
👍️0
LowFloatLopes LowFloatLopes 6 months ago
EMGE!!
👍️0
LowFloatLopes LowFloatLopes 6 months ago
I think you’re right lol I got out just after the whole thankfully I don’t fuck with halts lol come join EMGE it’s going bananas
👍️0
wickerman wickerman 6 months ago
$NEXI I think not.
👍️0
LowFloatLopes LowFloatLopes 6 months ago
U should …easy $25 min today imo
👍️0
wickerman wickerman 6 months ago
Heck yes awhile ago but didn't go long...congrats.
👍️0
LowFloatLopes LowFloatLopes 6 months ago
In at $16.60 LFG $25 before open
👍️0
LowFloatLopes LowFloatLopes 6 months ago
What do u mean lol
👍️0
Awl416 Awl416 6 months ago
Pyjama traders once again triggering those algos

Scary
👍️0
Awl416 Awl416 6 months ago
Uh oh
👍️0
Invest-in-America Invest-in-America 6 months ago
NEXI: NO "logic" nor "reason" of ANY fashion can be applied to Wall Street --- at its CORE!!! (No wonder most simply eyeball their charts, scanners, & volume --- all day long. Everything else is irelevant.)
👍️0
TheFinalCD TheFinalCD 6 months ago
https://investorplace.com/2024/01/neximmune-nexi-stock-rockets-80-ahead-of-potential-liquidation/
👍️0
bigfart bigfart 6 months ago
Nothing ventured nothing gained
👍️0
bigfart bigfart 6 months ago
I knew I should have gotten into this yesterday but it looked risky
👍️0
bigfart bigfart 6 months ago
Nice increase on relatively low volume
👍️0
subslover subslover 6 months ago
Nextimmune Inc (NASDAQ:NEXI) stock is up 170.2% to trade at $25.13, looking to extend its winning streak to three days as it stands at the top of the Nasdaq. Yesterday, NEXI added 73.8% following news that it expects its existing cash and cash equivalents to meet anticipated requirements through mid-February. Already in 2024, the stock is up more than 968%.
👍️0
Money hunt Money hunt 6 months ago
Hell yes dude!!!Foxo is next
👍️0
subslover subslover 6 months ago
I can't,I have outstanding speeding tickets. As of November 1, 2023, the registrant had 1,058,125 shares of common stock, $0.0001 par value per share, outstanding.
👍️0
trader59 trader59 6 months ago
Automated wash trading playing with the stock of a company that wants to dissolve itself. Don't get trapped.
👍️0
TheFinalCD TheFinalCD 6 months ago
$28 call the cops
👍️ 1
TheFinalCD TheFinalCD 6 months ago
you cover your short? https://investorplace.com/2024/01/neximmune-nexi-stock-rockets-80-ahead-of-potential-liquidation/
👍️0
TheFinalCD TheFinalCD 6 months ago
WHAT IN DE HELLLL
👍️0
Awl416 Awl416 6 months ago
Mayday!!!
👍️0
Invest-in-America Invest-in-America 6 months ago
NEXI: To the MOON, anyway!!!!
👍️0
Awl416 Awl416 6 months ago
Ahem
👍️0
Awl416 Awl416 6 months ago
Volatility
👍️0
Awl416 Awl416 6 months ago
Wild
👍️0
Awl416 Awl416 7 months ago
Again!
👍️0
da_stock_analyst da_stock_analyst 7 months ago
#NEXI 🔥 big run tomorrow? Watch SEC filing! $NEXI
👍️0
Awl416 Awl416 7 months ago
Fun day
👍️0
da_stock_analyst da_stock_analyst 7 months ago
#NEXI 🔥 watch tomorrow! small float crazy move today! $NEXI
👍️0
Awl416 Awl416 7 months ago
Lol
👍️0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
🍆 1 👎️ 1 🤡 1 🩳 1
Awl416 Awl416 7 months ago
Makes perfect sense…..👎
👍️0
Awl416 Awl416 7 months ago
Haha
👍️0
stock1ace1 stock1ace1 7 months ago
Lmfao P&D -> On December 21, 2023, NexImmune, Inc. (the “Company”) convened its special meeting of stockholders for the purpose of approving the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the “Special Meeting”).
👍️0
wickerman wickerman 8 months ago
$NEXI I'll cover and buy at .30 for the delisting bk bagholder bounce.
👍️0
Zhitong Zhitong 8 months ago
The global stock market will experience a rebirth amidst thorns in 2023! It aims to soar with the favorable wind in 2024.
The benchmark stock indices of the US, the S&P 500 Index, and the Nasdaq 100 Index, known as the "global technology stock indicators," have risen by approximately 20% and 46%, respectively, since 2023. Benefiting from the AI investment frenzy sparked by the emergence of ChatGPT last year, NVIDIA (NVDA.US) has become the hottest investment in the global stock market, with an astonishing 220% gain so far in 2023.

The "MSCI All Country World Index" (MSCI ACWI), representing the global stock market, has entered a rebound mode in 2023, with November marking the best monthly performance in over three years. The MSCI ACWI rose nearly 9% in November, achieving the best monthly performance since the 15% surge in November 2020. The index covers nearly 3,000 companies' stocks from 23 developed countries and 25 emerging markets, accounting for approximately 85% of each market's free-float adjusted market value.

Will 2024 be better for global stock market investors compared to 2023? According to the latest survey report by Bloomberg Markets Live Pulse (MLIV Pulse), the answer is affirmative.

The global stock markets, which have emerged from their darkest moments, are expected to continue their rebound in 2024.

2023 can be considered a year of "rebirth" for global stock market investors under heavy pressures such as high interest rates. The aggressive rate hike cycle initiated by central banks worldwide, including the U.S. Federal Reserve in 2022, pushed global stock markets into their darkest moments. In 2023, the AI investment frenzy that started in the first half of the year ignited endless imagination about tech stocks. Apart from NVIDIA's impressive performance, leaders in generative AI such as Microsoft (MSFT.US), Amazon (AMZN.US), and Meta Platforms (META.US) have seen gains of 56%, 75%, and even 170%, among many other tech stocks with similar performances.

Although some investment institutions warned of the possibility of stocks and other risk assets plummeting due to a recession in 2024, the majority of MLIV respondents predict a better performance for the global stock market next year. Among the 595 institutional and retail investors participating in the MLIV survey, an overwhelming 63% of retail investors expect stronger performance in their personal investment portfolios.

MLIV's survey reveals that this optimistic sentiment is based on the aggressive expectation that the Federal Reserve will cut interest rates by more than 100 basis points next year, continuing the rebound trend in global stock and bond markets seen in 2023. The current interest rate futures market expects the Fed to cut rates by at least 125 basis points next year, far higher than the expectation in November, clearing obstacles to declining U.S. bond yields and the continuous rise of risk assets such as stocks.

Additionally, recent annual outlook reports indicate that Wall Street is also very optimistic about next year's stock market prospects. The predictions for the S&P 500 Index, as the benchmark index of U.S. stocks and with a significant weight in the MSCI Global Index, reaching historic highs next year have been growing stronger recently. As of April 2023, U.S. stocks accounted for approximately 56% of the MSCI All Country World Index.

Strategists from Deutsche Bank Group AG and BMO Capital Markets have set the most optimistic target points on Wall Street to date. These two major institutions expect the S&P 500 Index to reach 5,100 points by the end of 2024, implying an approximately 11% increase from last week's closing. It is worth noting that Deutsche Bank and BMO Capital Markets are among the few Wall Street investment institutions that predicted the current rebound trend in the U.S. stock market. The S&P 500 Index reached its all-time high of 4,769.56 points in January 2022.

Strategists led by Lori Calvasina from RBC Capital Markets and Savita Subramanian from Bank of America expect the S&P 500 Index to rise to 5,000 points next year. Strategists from Goldman Sachs Group, one of the largest Wall Street banks, stated in their report that the S&P 500 Index, the benchmark index of U.S. stocks, is expected to continue its upward trend in 2024, and investors should maintain their exposure to stock assets, even during market fluctuations. In their latest report, Goldman Sachs emphasized that the returns of U.S. stocks next year will be concentrated in the second half of 2024. The expectations from Goldman Sachs' leading stock strategists, led by David Kostin, seem relatively moderate, predicting the S&P 500 Index to close at 4,700 points next year.

The main threat to the continued rebound in the stock market: Sticky inflation.

As the optimistic sentiment towards the global stock market is mainly driven by expectations of a future rate cut by the Federal Reserve-the market is betting on the earliest rate cut to start in March next year-the respondents generally recognize that the sticky inflation rate in the United States is the biggest threat to this situation, as it would prevent the Fed from implementing rate cuts.

At the individual investor level, 49% of respondents believe that rising living costs in 2024 are the biggest risk to their personal financial health. Although the year-on-year inflation rate has been slowing down, prices for food, groceries, and electricity in the United States have skyrocketed by 25% since January 2020, second-hand car prices have risen by 35%, and rent has increased by approximately 20%.

Furthermore, in the written comments of individual investors, unexpected medical expenses were cited as their biggest concern, along with adverse trends related to the insurance and financial industry investment compensations.

The hottest investment theme for 2024: AI.

Respondents, including top global fund managers and high-net-worth individual investors, overwhelmingly believe that the continuous breakthroughs in AI will continue to drive the innovation and growth of various industries, leading to new investment opportunities and higher returns.The breakthrough in artificial intelligence (AI) technology is a long-term source of profit. The stock price stimulation brought by the wave of AI has far exceeded any other theme this year, even surpassing the impact on stock prices by "weight loss miracles" such as Novo Nordisk A/S and Eli Lilly & Co.So far, the "artificial intelligence theme" is believed by surveyed investors to be the heavyweight trend for asset allocation in the next decade, with a staggering 67% of MLIV surveyed investors choosing artificial intelligence over cybersecurity, which received recognition from about 20% of respondents. Weight loss drugs briefly became headlines this year, but only 8% of respondents chose to invest in this theme.

Niall Gallagher, one of the top-performing fund managers in the European market, manages a stock fund under GAM Investments. In a survey consultation, he stated that in the past few months, he has reduced his positions in Novo Nordisk by about half, partly in response to the surge in valuation of appetite suppressant drugs. Shares of Novo Nordisk, a pharmaceutical giant from Denmark, have surged by 50% in 2023, with a current total market value of nearly $450 billion.

Although Gallagher pointed out that there are many short-term speculative factors about weight loss drugs, he said he still holds a relatively optimistic view of Novo Nordisk's medium- to long-term prospects.

There is a huge difference in sentiment surrounding another major trend, investment in large technology companies such as Apple, Microsoft, and Google. A large portion of respondents (45%) believe that the main logic behind investing in large technology stocks in 2024 is to bet on performance growth, so stock prices will have a bright performance, while 16% of people believe that these stocks are "safe havens". However, 39% of investors still believe that this is a bad bet and think that the value of these stocks is overestimated by the market.

Marta Norton, Chief Investment Officer of Morningstar Wealth in the Americas, stated that the generous returns in the technology industry this year have made it "valued at or near the highest level of unattractiveness to investors among all industries in the United States". Marta Norton stated that Morningstar Wealth's analysis shows that the US technology industry has embraced the boost from artificial intelligence. The long-term revenue growth assumption for these companies is about 200 basis points per year, and profit margins will increase by about 300 basis points in 10 years. "This perspective means that we can expect a continued strong sentiment for large technology companies in 2024, but this is not the bet we want to make right now."

Looking ahead to 2024, most investors tend to allocate funds to the stock and bond markets.

Most investors (57%) expect to change their asset allocation in 2024, with 31% planning to invest more funds in fixed income assets such as bonds, and 26% of investors stating that they will increase the weight of stocks in their portfolio, with some funds coming from salary increases or annual bonuses in 2024. A high proportion of 52% of respondents indicated a preference for stock and bond assets, with most of their funds being invested in stocks or bonds.

However, cash assets still hold investment appeal. Nearly a quarter of respondents will keep most of their bonuses in cash, and 19% of respondents will use the bonuses to pay bills or repay debts. Only 5% of respondents expect to spend the funds on big-ticket items such as buying cars or going on vacation. Overall, 38% of respondents expect to increase their savings next year, while less than one-fifth of respondents expect to decrease their savings.

Most respondents said their bonuses or extra funds will be used to buy stocks or bonds.

Many MLIV respondents believe that the upcoming US presidential election is irrelevant to their financial situation, with 47% of respondents expecting no significant impact from the November election. Among the remaining respondents, 27% said their financial situation would be more severely affected if former President Donald Trump wins, while 26% of respondents said it would be worse if Joe Biden is successfully reelected.

Most respondents believe that the election battle between Trump and Biden is irrelevant to their personal finances.

A recent report by Lori Calvasina, head of US equity strategy at RBC Capital Markets, showed that the average increase in the S&P 500 Index in presidential election years is around 7.5%, lower than the trendline level and also lower than the typical return rate of 13.5% in the third year of a presidential term. Calvasina pointed out in the report that the typical pattern is weak at the beginning of the year, rebounding before autumn, market volatility approaching election day, and a rebound after the election. Calvasina's target for the S&P 500 Index at the end of next year is a historic high of 5,000 points.

"Any given US presidential election year is one of the important sources of uncertainty for the US stock market." Calvasina wrote in the report. "Considering all the unusual aspects of the 2024 US election, this seems to be an appropriate way to think about the political background in which the stock market will be in 2024."
👍️0

Your Recent History

Delayed Upgrade Clock